Abbott Laboratories Inc.

Abbott Laboratories Inc., through its Abbott Diagnostics Division (operating as Abbott Nutrition), manufactures and supplies clinical laboratory analyzers, reagents, consumables, and diagnostic equipment to federal healthcare agencies as a prime contractor on full-and-open competition, without small business set-asides. A large for-profit corporation headquartered in Lake Bluff, Illinois, Abbott Diagnostics competes across the unrestricted federal marketplace and holds dominant market position in federal clinical laboratory procurement, particularly within the Department of Veterans Affairs regional networks and the Defense Health Agency.

Abbott's federal footprint centers on cost-per-reportable-result chemistry and immunoassay analyzer systems, blood product screening reagents, infectious disease testing capabilities, and associated clinical laboratory consumables. Representative prime work includes a $9.17 million delivery order from Veterans Integrated Service Network 8 for lab cost-per-test chemistry and immunoassay analyzer services through October 31, 2031, under the GSA Critical Analyzers, Laboratory (FSS-66-III) schedule; a $4.78 million delivery order from VISN 22 for chemistry and immunoassay system support at the Northern Arizona VA Health Care System through September 16, 2026; a $9.13 million delivery order from VISN 22 for a chemistry immunoassay system at Phoenix through October 6, 2026; a $3.13 million delivery order from the Defense Health Agency for cost-per-test chemistry and immunoassay analyzer services through September 30, 2027; and a $7.14 million delivery order from VISN 20 for cost-per-reportable-result laboratory supplies through June 30, 2029. Abbott also holds an $803,192 five-year sole-source purchase order from the CDC Pittsburgh for Alinity maintenance and supplies through June 24, 2031, and a $4.48 million definitive contract from the Defense Health Agency for chemistry analyzers and reagents through May 31, 2031.

Customer concentration sits heavily with the VA regional networks. The top five customer agencies by potential value account for approximately 24% of combined potential value: Veterans Integrated Service Network 15 ($416.1 million across 137 awards), VISN 9 ($382.2 million across 189 awards), VISN 8 ($177.2 million across 224 awards), VISN 1 ($173.6 million across 236 awards), and the Defense Health Agency ($138 million across 104 awards). By award count, Defense Logistics Agency Troop Support Medical anchors the volume (1,931 awards, $25 million combined potential value), followed by the Department of Veterans Affairs broadly (581 awards, $31.2 million), VISN 23 (307 awards, $60.1 million), the Indian Health Service (278 awards, $19.5 million), and the Department of the Navy Bureau of Medicine and Surgery (247 awards, $30.2 million). Abbott serves 119 distinct federal customer agencies across its prime footprint.

Abbott's vehicle position reflects concentration on the GSA Critical Analyzers, Laboratory (FSS-66-III) Federal Supply Schedule, which carries 1,275 task orders valued at $1.68 billion in combined potential value and represents Abbott's primary vehicle across federal health customers. Two additional GSA Federal Supply Schedules anchor significant volume: FSS-V797P4742A (2,799 task orders, $356 million combined potential value) and FSS-V797P5478X (2,673 task orders, $372.7 million combined potential value). Abbott also holds numerous single-award BPAs and indefinite delivery contracts with individual VA Integrated Service Networks—including a $59.69 million BPA with VISN 9 for immunochemistry lab cost-per-reportable-result services through September 30, 2033, a $8.97 million IDC with the Defense Health Agency for Alinity S blood and plasma analyzer reagents through September 30, 2030, a $17.75 million BPA with VISN 23 for chemistry lab testing through June 30, 2027, a $15.87 million BPA with VISN 2 for chemistry and immunoassay cost-per-reportable-result services through March 31, 2027, and a $8.26 million BPA with VISN 5 for cost-per-reportable-result chemistry services through June 17, 2031.

Activity has remained relatively stable year over year (2022: 118 awards; 2025: 136 awards), with 72 awards recorded in 2026 through early October. Sixty awards (combined potential value $92.5 million) reach ultimate completion within the next twenty-four months, representing significant recompete opportunity in the federal clinical laboratory procurement space. Abbott's subcontract footprint is minimal (1% of total awards): the company subcontracts under Cardinal Health 200, LLC as a prime for medical and surgical equipment and supplies, representing approximately two dozen sub-awards dating back to mid-2024.

Abbott's federal award portfolio spans five primary NAICS categories: Medical Laboratories (3,033 awards), In-Vitro Diagnostic Substance Manufacturing (2,929 awards), Analytical Laboratory Instrument Manufacturing (1,570 awards), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (1,228 awards), and Surgical and Medical Instrument Manufacturing (824 awards). Primary PSC codes align with Medical And Surgical Instruments, Equipment, And Supplies (3,994 awards), In Vitro Diagnostic Substances, Reagents, Test Kits And Sets (2,584 awards), Laboratory Equipment And Supplies (2,353 awards), and Chemical Analysis Instruments (920 awards). Abbott Laboratories (parent) is the corporate parent to Abbott Laboratories Inc. and holds a named subsidiary, Abbott Molecular Inc.